Phase III trials consistently showed superior efficacy of first- (e.g., erlotinib) and second-generation (e.g., afatinib) TKIs over standard chemotherapies (e.g., platinum-based) for patients with EGFR-mutated (EGFRmut+) NSCLC, improving progression-free survival (PFS) from 6 months up to 15 months 2-6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.